

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number  
**WO 2005/084670 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4184**,  
31/695, 9/28, C07D 403/10

(21) International Application Number:  
PCT/EP2005/002108

(22) International Filing Date: 28 February 2005 (28.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
P200400067 1 March 2004 (01.03.2004) SI

(71) Applicant (for all designated States except US): **LEK  
PHARMACEUTICALS D.D.** [SI/SI]; Verovskova 57,  
1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SVETE, Pe-  
ter** [SI/SI]; Gradisnikova 14, 1353 Borovnica (SI).  
**GRAHEK, Rok** [SI/SI]; Zoisova 17, 4000 Kranj (SI).  
**HUMAR, Vlasta** [SI/SI]; Godic 63, 1242 Stahovica (SI).  
**HUSU-KOVACEVIC, Breda** [SI/SI]; Na peci 27, 1000  
Ljubljana (SI). **JERALA-STRUKE LJ, Zdenka** [SI/SI];  
Podreca 107, 4211 Mavcice (SI).

(74) Agent: **THOMSEN, Peter**; Novartis AG, Corporate Intel-  
lectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATION

(57) Abstract: Composition were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcrystalline cellulose, magnesium oxide and polyethylene glycol.

WO 2005/084670 A1